Related references
Note: Only part of the references are listed.Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2
Ranjan K. Singh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)
LRRK2 dynamics analysis identifies allosteric control of the crosstalk between its catalytic domains
Jui-Hung H. Weng et al.
PLOS BIOLOGY (2022)
Pathogenic LRRK2 regulates ciliation probability upstream of tau tubulin kinase 2 via Rab10 and RILPL1 proteins
Yuriko Sobu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Pathogenic LRRK2 control of primary cilia and Hedgehog signaling in neurons and astrocytes of mouse brain
Shahzad S. Khan et al.
ELIFE (2021)
LRRK2-phosphorylated Rab10 sequesters Myosin Va with RILPL2 during ciliogenesis blockade
Herschel S. Dhekne et al.
LIFE SCIENCE ALLIANCE (2021)
Allosteric Inhibition of Parkinson's-Linked LRRK2 by Constrained Peptides
Leah G. Helton et al.
ACS CHEMICAL BIOLOGY (2021)
Structural analysis of the full-length human LRRK2
Alexander Myasnikov et al.
CELL (2021)
LRRK2 in Parkinson disease: challenges of clinical trials
Eduardo Tolosa et al.
NATURE REVIEWS NEUROLOGY (2020)
Allosteric modulation of the GTPase activity of a bacterial LRRK2 homolog by conformation-specific Nanobodies
Margaux Leemans et al.
BIOCHEMICAL JOURNAL (2020)
The Parkinson's Disease Protein LRRK2 Interacts with the GARP Complex to Promote Retrograde Transport to the trans-Golgi Network
Alexandra Beilina et al.
CELL REPORTS (2020)
The In Situ Structure of Parkinson's Disease-Linked LRRK2
Reika Watanabe et al.
CELL (2020)
Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity
An Phu Tran Nguyen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Structure of LRRK2 in Parkinson's disease and model for microtubule interaction
C. K. Deniston et al.
NATURE (2020)
LRRK2 links genetic and sporadic Parkinson's disease
Jillian H. Kluss et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2019)
Parkinson's disease-associated mutations in the GTPase domain of LRRK2 impair its nucleotide-dependent conformational dynamics
Chun-Xiang Wu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Recent Developments in LRRK2-Targeted Therapy for Parkinson's Disease
Ye Zhao et al.
DRUGS (2019)
Structure and nucleotide-induced conformational dynamics of the Chlorobium tepidum Roco protein
Egon Deyaert et al.
BIOCHEMICAL JOURNAL (2019)
The Parkinson's disease-associated mutation N1437H impairs conformational dynamics in the G domain of LRRK2
Xiaorong Huang et al.
FASEB JOURNAL (2019)
LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients
Daniel Ysselstein et al.
NATURE COMMUNICATIONS (2019)
Molecular mechanism of ATP versus GTP selectivity of adenylate kinase
Per Rogne et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
A homologue of the Parkinson's disease-associated protein LRRK2 undergoes a monomer-dimer transition during GTP turnover
Egon Deyaert et al.
NATURE COMMUNICATIONS (2017)
Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases
Martin Steger et al.
ELIFE (2016)
Revisiting the Roco G-protein cycle
Susanne Terheyden et al.
BIOCHEMICAL JOURNAL (2015)
Effect of selective LRRK2 kinase inhibition on nonhuman primate lung
Reina N. Fuji et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models
Tianxia Li et al.
HUMAN MOLECULAR GENETICS (2014)
Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1
Nathaniel Weygant et al.
MOLECULAR CANCER (2014)
Parkinson disease-associated mutation R1441H in LRRK2 prolongs the active state of its GTPase domain
Jingling Liao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Dynamic architecture of a protein kinase
Christopher L. McClendon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease
Alexandria Beilina et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2
Alice Biosa et al.
HUMAN MOLECULAR GENETICS (2013)
Leucine-Rich Repeat Kinase 2 (LRRK2)-Deficient Rats Exhibit Renal Tubule Injury and Perturbations in Metabolic and Immunological Homeostasis
Daniel Ness et al.
PLOS ONE (2013)
Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?
Iakov N Rudenko et al.
BMC Medicine (2012)
LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6
Daniel C. Berwick et al.
HUMAN MOLECULAR GENETICS (2012)
Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway
Youren Tong et al.
MOLECULAR NEURODEGENERATION (2012)
Ser1292 Autophosphorylation Is an Indicator of LRRK2 Kinase Activity and Contributes to the Cellular Effects of PD Mutations
Zejuan Sheng et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice
Martin C. Herzig et al.
HUMAN MOLECULAR GENETICS (2011)
LRRK2 R1398H polymorphism is associated with decreased risk of Parkinson's disease in a Han Chinese population
Ling Chen et al.
PARKINSONISM & RELATED DISORDERS (2011)
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization
R. Jeremy Nichols et al.
BIOCHEMICAL JOURNAL (2010)
Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease
Byoung Dae Lee et al.
NATURE MEDICINE (2010)
LRRK2 and neurodegeneration
Gabriel Santpere et al.
ACTA NEUROPATHOLOGICA (2009)
Characterization of a Ras Mutant with Identical GDP- and GTP-Bound Structures
Bradley Ford et al.
BIOCHEMISTRY (2009)
LRRK2 p.G2019S mutation is not common among Alzheimer's disease patients in Brazil
Cintia Barros Santos-Reboucas et al.
DISEASE MARKERS (2009)
Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment
Christian L. Klein et al.
JOURNAL OF NEUROCHEMISTRY (2009)
Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease
Owen A. Ross et al.
ANNALS OF NEUROLOGY (2008)
Structure of the Roc-COR domain tandem of C-tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase
Katja Gotthardt et al.
EMBO JOURNAL (2008)
LRRK2 regulates synaptic vesicle endocytosis
Narae Shin et al.
EXPERIMENTAL CELL RESEARCH (2008)
Intramolecular Activation Mechanism of theDictyosteliumLRRK2 Homolog Roco Protein GbpC
Wouter N. van Egmond et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
LRRK2 Gly2385Arg mutation and clinical features in a Chinese population with early-onset Parkinson's disease compared to late-onset patients
Daniel Kam Yin Chan et al.
JOURNAL OF NEURAL TRANSMISSION (2008)
The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity
Luxuan Guo et al.
EXPERIMENTAL CELL RESEARCH (2007)
LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity
Mahaboobi Jaleel et al.
BIOCHEMICAL JOURNAL (2007)
GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease
Genta Ito et al.
BIOCHEMISTRY (2007)
Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity
Andrew B. West et al.
HUMAN MOLECULAR GENETICS (2007)
Localization of LRRK2 to membranous and vesicular structures in mammalian brain
Saskia Biskup et al.
ANNALS OF NEUROLOGY (2006)
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin
Elisa Greggio et al.
NEUROBIOLOGY OF DISEASE (2006)
A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan
Alessio Di Fonzo et al.
NEUROGENETICS (2006)
The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity
CJ Gloeckner et al.
HUMAN MOLECULAR GENETICS (2006)
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
AB West et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients
EK Tan et al.
NEUROSCIENCE LETTERS (2005)
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease
C Paisán-Ruíz et al.
NEURON (2004)
Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology
A Zimprich et al.
NEURON (2004)
Roc, a Ras/GTPase domain in complex proteins
L Bosgraaf et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2003)
A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1
M Funayama et al.
ANNALS OF NEUROLOGY (2002)
Signal transduction - The guanine nucleotide-binding switch in three dimensions
IR Vetter et al.
SCIENCE (2001)
Share Paper
